Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)

Research Progress of CAR-T Therapy in Tumor Therapy

Authors
Jingyu Zhao1, *
1College of Bioengineering, Tianjin University of Science and Technology, Tianjin, 300450, China
*Corresponding author. Email: jz74@hw.ac.uk
Corresponding Author
Jingyu Zhao
Available Online 29 December 2022.
DOI
10.2991/978-2-494069-31-2_7How to use a DOI?
Keywords
CAR-T therapy; tumor; CAR construction; targets; problems and solutions
Abstract

New progress is constantly being made in the field of tumor treatment, and new advances are constantly being made. Among them, chimeric antigen receptor T cell (CAR-T) immunotherapy is a gene therapy method that expresses transmembrane chimeric antigen receptors by gene editing and redirects T cells to recognize tumor cells specifically. CAR-T cells can kill tumor cells effectively so as to achieve the aim of treating malignant tumors. This is a highly promising approach to cancer immunotherapy that is precise, rapid, efficient, and has the potential to cure cancer. This paper summarizes the development course and research progress of CAR-T therapy and illustrates important targets of CAR-T cells in tumor treatment, such as CD19, prostate specific membrane antigen, human epidermal growth factor receptor-2, etc. Meanwhile, the paper presents the current problems facing CAR-T cell immunotherapy, such as the toxicity of CAR-T therapy, the exhaustion of CAR-T cells and their safety, as well as the corresponding effective solutions. The paper will use tumor specific antigen as a target or design double target CAR-T cells to deal with off-target toxicity. Besides, it regulates CAR-T cell activity in vivo to reduce CRS. The results indicate that blocking checkpoints or inhibiting exhaustion-related transcription factors can resist exhaustion. Further process optimization can improve the carrier's safety.

Copyright
© 2022 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

Volume Title
Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)
Series
Advances in Social Science, Education and Humanities Research
Publication Date
29 December 2022
ISBN
978-2-494069-31-2
ISSN
2352-5398
DOI
10.2991/978-2-494069-31-2_7How to use a DOI?
Copyright
© 2022 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

TY  - CONF
AU  - Jingyu Zhao
PY  - 2022
DA  - 2022/12/29
TI  - Research Progress of CAR-T Therapy in Tumor Therapy
BT  - Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)
PB  - Atlantis Press
SP  - 49
EP  - 58
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-494069-31-2_7
DO  - 10.2991/978-2-494069-31-2_7
ID  - Zhao2022
ER  -